NCOA5在40例甲状腺乳头状癌中的表达及临床意义
|
摘要
[目的]探讨NCOA5蛋白在甲状腺乳头状癌中的表达及临床意义。[方法]应用免疫组化方法(SP法)检测NCOA5蛋白在40例甲状腺乳头状癌组织及配对癌旁甲状腺组织中的表达,并探讨其与临床病理特征及预后的关系。[结果] NCOA5蛋白在甲状腺癌组织中的阳性表达率(75%)高于癌旁组织(20%)(χ~2=24.261,P<0.01)。NCOA5表达与肿瘤分期(TNM分期)和淋巴结转移有关(χ~2=4.126,P<0.05;χ~2=4.043,P<0.05);与甲状腺乳头状癌的预后指数呈正相关(r=5.647,P<0.05)。[结论] NCOA5在甲状腺乳头状癌中高表达,对甲状腺癌的诊疗和预后评估具有指导意义。
引文
[1]Moses W,Weng J,Sansano I,et al.Molecular testing for somatic mutations improves the accuracy of thyroid fineneedle aspiration biopsy[J].World J Surg,2010,34(11):2589-2594.
[2]Zhang YH,Bao JC,Qiu FP,et al.The expression and clinical significance of c-Met,HIF-1αin thyroid papillary carcinoma[J].Journal of Chinese Oncology,2013,15(1):26-29.[张彦惠,鲍建昌,邱法鹏,等.c-Met、HIF-1α在甲状腺乳头状癌中的表达及临床意义[J].肿瘤学杂志,2013,15(1):26-29.]
[3]Sun SS,Qiu J,Zhao H,et al.ZNF703 and CD44v6 expression and significance in thyroid papillary carcinoma[J].Journal of Chinese Oncology,2018,24(4):303-307.[孙莎莎,邱杰,赵涵,等.ZNF703和CD44v6在甲状腺乳头状癌中的表达和意义[J].肿瘤学杂志,2018,24(4):303-307.]
[4]Byar DP,Green SB,Dor P,et al.A prognostic index for thyroid carcinoma.a study of the E.O.R.T.C.Thyroid Cancer Cooperative Group[J].Eur J Cancer,1979,15(8):1033-1041.
[5]Lu Y,Li YD,Chen GC,et al.Nuclear receptor coactivator and its transcriptional regulation[J].Journal of Clinical and Pathological Research,2005,25(1):24-27.[卢莹,李忆东,陈光椿,等.核受体共激活因子及其转录调节[J].临床与病理杂志,2005,25(1):24-27.]
[6]Liu CY,Feng GS.NCOA5,a molecular link between type2 diabetes and liver cancer[J].Hepatobiliary Surg Nutr,2014,3(3):106-108.
[7]Gillespie MA,Gold ES,Ramsey SA,et al.An LXR-NCOA5 gene regulatory complex directs inflammatory crosstalk-dependent repression of macrophage cholesterol efflux[J].EMBO J,2015,34(9):1244-1258.
[8]Zhang HP,Cao SL,Li GQ,et al.Expression and clinical significance of nuclear receptor co-activator 5 in hepatocelluar carcinoma[J].Chinese Journal of Cancer Prevention and Treatment,2015,22(1):45-48.[张华鹏,曹胜利,李功权,等.肝细胞癌组织核受体辅激活蛋白5表达临床意义探讨[J].中华肿瘤防治杂志,2015,22(1):45-48.]
[9]Chen GQ,Tian H,Yue WM,et al.NCOA5 low expression correlates with survival in esophageal squamous cell carcinoma[J].Med Oncol,2014,31(12):376.
[10]Ye XH,Huang DP,Luo RC.NCOA5 is correlated with progression and prognosis in luminal breast cancer[J].Biochem Biophys Res Commun,2016,477(4):923-926.
[11]Sun KL,Qin L.Expression,function and mechanism of NCOA5 in colorectal cancer[D].Suzhou:Soochow University,2015.[孙凯律,秦磊.NCOA5在结直肠癌中的表达、功能及机制研究[D].苏州:苏州大学,2015.]
[12]Zhou JD.Expression of coactivators in papillary thyroid carcinoma and its clinical significance[J].Journal of North Pharmacy,2016,(1):119.[周锦都.共激活因子在甲状腺乳头状癌中的表达及其临床意义[J].北方药学,2016,(1):119.]
[13]Lv CY,Liao MG,Zhang LL,et al.Clinical assessment of cervical lymph node metastasis in papillary thyroid carcinoma[J].Journal of Chinese Oncology,2018,24(4):297-302.[吕春艳,廖曼各,张丽林,等.甲状腺乳头状癌颈部淋巴结转移的临床评估进展[J].肿瘤学杂志,2018,24(4):297-302.]
[2]Zhang YH,Bao JC,Qiu FP,et al.The expression and clinical significance of c-Met,HIF-1αin thyroid papillary carcinoma[J].Journal of Chinese Oncology,2013,15(1):26-29.[张彦惠,鲍建昌,邱法鹏,等.c-Met、HIF-1α在甲状腺乳头状癌中的表达及临床意义[J].肿瘤学杂志,2013,15(1):26-29.]
[3]Sun SS,Qiu J,Zhao H,et al.ZNF703 and CD44v6 expression and significance in thyroid papillary carcinoma[J].Journal of Chinese Oncology,2018,24(4):303-307.[孙莎莎,邱杰,赵涵,等.ZNF703和CD44v6在甲状腺乳头状癌中的表达和意义[J].肿瘤学杂志,2018,24(4):303-307.]
[4]Byar DP,Green SB,Dor P,et al.A prognostic index for thyroid carcinoma.a study of the E.O.R.T.C.Thyroid Cancer Cooperative Group[J].Eur J Cancer,1979,15(8):1033-1041.
[5]Lu Y,Li YD,Chen GC,et al.Nuclear receptor coactivator and its transcriptional regulation[J].Journal of Clinical and Pathological Research,2005,25(1):24-27.[卢莹,李忆东,陈光椿,等.核受体共激活因子及其转录调节[J].临床与病理杂志,2005,25(1):24-27.]
[6]Liu CY,Feng GS.NCOA5,a molecular link between type2 diabetes and liver cancer[J].Hepatobiliary Surg Nutr,2014,3(3):106-108.
[7]Gillespie MA,Gold ES,Ramsey SA,et al.An LXR-NCOA5 gene regulatory complex directs inflammatory crosstalk-dependent repression of macrophage cholesterol efflux[J].EMBO J,2015,34(9):1244-1258.
[8]Zhang HP,Cao SL,Li GQ,et al.Expression and clinical significance of nuclear receptor co-activator 5 in hepatocelluar carcinoma[J].Chinese Journal of Cancer Prevention and Treatment,2015,22(1):45-48.[张华鹏,曹胜利,李功权,等.肝细胞癌组织核受体辅激活蛋白5表达临床意义探讨[J].中华肿瘤防治杂志,2015,22(1):45-48.]
[9]Chen GQ,Tian H,Yue WM,et al.NCOA5 low expression correlates with survival in esophageal squamous cell carcinoma[J].Med Oncol,2014,31(12):376.
[10]Ye XH,Huang DP,Luo RC.NCOA5 is correlated with progression and prognosis in luminal breast cancer[J].Biochem Biophys Res Commun,2016,477(4):923-926.
[11]Sun KL,Qin L.Expression,function and mechanism of NCOA5 in colorectal cancer[D].Suzhou:Soochow University,2015.[孙凯律,秦磊.NCOA5在结直肠癌中的表达、功能及机制研究[D].苏州:苏州大学,2015.]
[12]Zhou JD.Expression of coactivators in papillary thyroid carcinoma and its clinical significance[J].Journal of North Pharmacy,2016,(1):119.[周锦都.共激活因子在甲状腺乳头状癌中的表达及其临床意义[J].北方药学,2016,(1):119.]
[13]Lv CY,Liao MG,Zhang LL,et al.Clinical assessment of cervical lymph node metastasis in papillary thyroid carcinoma[J].Journal of Chinese Oncology,2018,24(4):297-302.[吕春艳,廖曼各,张丽林,等.甲状腺乳头状癌颈部淋巴结转移的临床评估进展[J].肿瘤学杂志,2018,24(4):297-302.]